# Thymalfasin and Recombinant Human IL-2 Injections in Treating Lymphocytopenia for Patients With Malignant Hematological Tumors

> **NCT06584006** · PHASE2 · RECRUITING · sponsor: **The First Affiliated Hospital of Xiamen University** · enrollment: 50 (estimated)

## Conditions studied

- Hematological Malignancy
- Lymphocytopenia

## Interventions

- **DRUG:** Thymalfasin for injection in combination with Recombinant Human Interleukin-2 Injections
- **DRUG:** Recombinant Human Interleukin-2 Injections

## Key facts

- **NCT ID:** NCT06584006
- **Lead sponsor:** The First Affiliated Hospital of Xiamen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-01
- **Primary completion:** 2027-11-30
- **Final completion:** 2028-02-29
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06584006

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06584006, "Thymalfasin and Recombinant Human IL-2 Injections in Treating Lymphocytopenia for Patients With Malignant Hematological Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06584006. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*